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Abstract
Background The last decade has seen the increasing use of biological medicines in combination with chemotherapy contain-
ing 5-fluorouracil/oxaliplatin or irinotecan for the treatment of metastatic colorectal cancer (mCRC). These combinations 
have resulted in increased progression-free survival (PFS) in patients with mCRC; however, there are remaining concerns 
over the extent of their effect on overall survival (OS). Published studies to date suggest no major differences between the 
three currently available monoclonal antibodies (MoAbs); however, there are differences in costs. In addition, there is rising 
litigation in Brazil in order to access these medicines as they are currently not reimbursed.
Objective The aim was to investigate the comparative effectiveness and safety of three MoAbs (bevacizumab, cetuximab 
and panitumumab) associated with fluoropyrimidine-based chemotherapy regimens and compared to fluoropyrimidine-based 
chemotherapy alone in patients with mCRC, through an updated systematic review and meta-analysis of concurrent or non-
concurrent observational cohort studies, to guide authorities and the judiciary.
Method A systematic review and meta-analysis was performed based on cohort studies published in databases up to Novem-
ber 2017. Effectiveness measures included OS, PFS, post-progression survival (PPS), Response Evaluation Criteria In Solid 
Tumors (RECIST), response rate, metastasectomy and safety. The methodological quality of the studies was also evaluated.
Results A total of 21 observational cohort studies were included. There were statistically significant and clinically relevant 
benefits in patients treated with bevacizumab versus no bevacizumab mainly around OS, PFS, PPS and the metastasectomy 
rate, but not for the disease control rates. However, there was an increase in treatment-related toxicities and concerns with 
the heterogeneity of the studies.
Conclusion The results pointed to an advantage in favor of bevacizumab for OS, PFS, PPS, and metastasectomy. Although 
this advantage may be considered clinically modest, bevacizumab represents a hope for increased survival and a chance of 
metastasectomy for patients with mCRC. However, there are serious adverse events associated with its use, especially severe 
hypertension and gastrointestinal perforation, that need to be considered.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 9-018-0322-1) contains 
supplementary material, which is available to authorized users.
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Key Points 
The use of monoclonal antibodies (MoAbs) as a thera-
peutic option for metastatic colorectal cancer (mCRC) 
created expectations for greater overall survival as well 
as decreased toxicity and grade ≥ 3 adverse event com-
plications compared with cytotoxic chemotherapy.
The results of the studies included in this meta-analysis 
showed increased overall survival, progression-free 
survival and metastasectomy rate in patients with mCRC 
using MoAbs; however, there was great heterogeneity in 
the studies and severe adverse events.
It is important to assess the value and cost of interven-
tions for both first- and second-line treatments when 
making choices. Marginal gains with associated high 
costs are difficult to justify within universal healthcare 
systems.
1 Introduction
Cancer is one of the leading causes of death worldwide, 
with more than 8.8 million deaths in 2015, up from 8.2 mil-
lion deaths in 2012 [1, 2], with breast, colorectal, lung, and 
stomach cancers the most commonly diagnosed cancers. 
The overall economic burden of cancer was estimated at 
US$1.6 trillion in 2010 and rising [2]. Colorectal cancer 
(CRC) continues to be a worldwide public health problem, 
with the number of new cases per year of CRC in 2012 at 
1.36 million [3, 4], corresponding to 10% of patients diag-
nosed with cancer in 2012. Overall, CRC is the third most 
common neoplasm in men and the second most common in 
women [5], with 694,000 deaths in 2012 [3].
CRC is a curable disease if diagnosed in early stages [6]. 
However, between 70 and 90% of CRC cases are currently 
diagnosed in advanced stages of the disease, resulting in 
initiatives including biomarkers to help identify patients 
earlier [5–8].
Since the 1990 s, fluoropyrimidine-based chemotherapy 
(CT) (5-fluorouracil [5-FU] or capecitabine) has been the 
principal treatment for CRC, with demonstrated benefits 
in overall survival (OS) [9, 10]. Irinotecan and oxaliplatin 
are widely used in combination with 5-FU and leucovorin 
(folinic acid) as first- or second-line treatment for meta-
static CRC (mCRC) [11, 12], with studies demonstrating 
their addition as first-line treatment improves median sur-
vival by 2–4 months [9, 11]. Whilst 5-FU and oxalipl-
atin have improved survival rates, this combination has 
resulted in a higher incidence of severe adverse events, 
however, with acceptable tolerability and maintenance of 
quality of life [11].
The use of molecular biological agents, monoclonal 
antibodies (MoAbs), in combination with 5-FU/oxaliplatin 
or irinotecan has become widespread to try and improve 
survival rates in patients with mCRC [6, 12–15]. However, 
the biological medicines have appreciably increased the 
cost of medicines with the high costs of MoAbs, often 
with limited health gain versus current standards. The high 
cost of biological medicines coupled with growing cancer 
prevalence rates have resulted in concerns for the future 
sustainability of healthcare systems [16–23].
The MoAbs used to treat patients with mCRC include 
cetuximab (CETUX) and panitumumab (PANIT) [5, 
14], which act on the epidermal growth factor receptor 
(EGFR), and bevacizumab (BEVA) [5], which acts on 
the vascular endothelial growth factor (VEGF) [5, 24]. 
They have all improved progression-free survival (PFS) 
in patients with mCRC; however, there have been con-
cerns expressed regarding the extent of their effectiveness 
with improving OS [14] and their cost-effectiveness [25, 
26]. Theoretically, payers of healthcare should not grant 
high prices for new cancer medicines that improve PFS 
but have limited or no improvement on OS, as this will 
affect available resources for other high-priority disease 
areas [27]. However, this has to be balanced against the 
emotive nature of the disease and the anxiety that patients 
with cancer have [28].
Improved targeting of high-priced biological medicines 
could potentially address these concerns. According to Rou-
gier and Mitry [10], MoAbs are restricted to patients without 
the Kirsten rat sarcoma viral oncogene (KRAS) and N-RAS 
oncogene mutations [29, 30]. Overall, approximately 45% of 
patients with mCRC with wild-type KRAS are resistant to 
treatment with CETUX [31]. Consequently, KRAS testing 
before CETUX can conserve resources [32–34].
The National Institute for Health and Care Excellence 
(NICE) in the UK currently recommends the use of CETUX 
and PANIT as an option for previously untreated anti-EGFR 
wild-type metastatic RAS in association with FOLFOX 
(folinic acid, 5-FU, oxaliplatin) or FOLFIRI (folinic acid, 
5-FU, irinotecan). BEVA is currently not recommended 
for use in the UK, either in combination with intravenous 
5-FU/folinic acid or with FOLFIRI for first-line treatment 
of patients with metastatic carcinoma of the colon or rectum 
[35–37]. Australia’s Pharmaceutical Benefits Scheme does 
not mention BEVA for mCRC; however, it is indicated for 
epithelial ovarian, fallopian tube or primary peritoneal can-
cer [38, 39]. CETUX in combination with FOLFIRI has been 
approved by the Canadian Agency for Drugs and Technolo-
gies in Health for first-line treatment in patients with mCRC 
and KRAS wild-type (KRAS-WT) oncogenes [40]. NICE do 
not recommend CETUX (monotherapy or combination CT), 
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BEVA (in combination with non-oxaliplatin CT) and PANIT 
(monotherapy) for mCRC after first-line CT [41].
However, BEVA was considered by the  Avastin® Reg-
istry—Investigation of Effectiveness and Safety (ARIES) 
observational cohort study as a potential treatment for the 
mCRC in recent years [42].
A number of meta-analyses and other studies have shown 
no difference in health gain between these three MoAbs in 
mCRC patients [41–43]. Three systematic reviews, Hapani 
et al. [43], Lv et al. [44], and Rosa et al. [45], have also 
shown no additional clinical benefit with BEVA com-
pared with CT, i.e., FOLFORI or FOLFOX, or BEVA with 
CETUX or PANIT, in terms of increased efficacy or reduced 
side effects. However, a sub-study by Hurwitz et al. [46] 
confirmed the effectiveness of BEVA in the KRAS-WT sub-
group of mCRC patients. This compares with the meta-anal-
ysis of Wagner et al. [47], who evaluated five randomized 
clinical trials (RCTs) with 3101 participants comparing 
BEVA versus no BEVA for first-line CT, which showed 
significant benefits for OS or PFS in favor of BEVA-treated 
patients. We note though that in the no BEVA group, in addi-
tion to CT regimens, the authors included vatalanib (another 
VEGF inhibitor), which was not included in our review. In 
addition, there was a high incidence of grade 3 and 4 adverse 
events including hypertension, arterial thromboembolic 
events and gastrointestinal perforations in patients treated 
with BEVA [43, 47].
Currently, in the Brazilian health system (Sistema Único 
de Saúde [SUS]), BEVA, CETUX and PANIT can only 
be used and funded after successful litigation against the 
state, or 100% co-payment, since they are not incorporated 
into the health system. The Brazilian Health Technology 
Assessment Agency of SUS (Comissão Nacional de Incor-
poração de Tecnologias no SUS [CONITEC]) did not rec-
ommend the incorporation of CETUX for the management 
of mCRC in view of concerns with its price and limited 
health gain, and currently, BEVA and PANIT have not yet 
been evaluated for inclusion into SUS [48]. In view of this, 
successful litigation is the only means for patients to have 
these treatments funded within SUS. In the state of Minas 
Gerais (MG), public expenditure on BEVA, CETUX and 
PANIT as a result of successful litigation was approximately 
US$20 million between 2009 and 2016 (Fig. 1E in the elec-
tronic supplementary material). This is a concern as these 
monies are not available for cost-effective medicines in 
other high-priority disease areas. Currently, the ex-factory 
monthly treatment costs based on prices from Câmara de 
Regulação do Mercado de Medicamentos (CMED) Agência 
Nacional de Vigilância Sanitária (ANVISA) [49] are BEVA 
U$2897.90, CETUX US$6585.10 and PANIT US$3100.20. 
Consequently, CETUX is more expensive than BEVA by 
127% and more expensive than PANIT by 112%. PANIT is 
more expensive than BEVA by 6%.
Faced with the contradictory scenario regarding the use 
of MoAbs in mCRC, as well as considerable differences 
in prices between these three and versus standard CT, the 
objective of this study was to evaluate the effectiveness 
and safety of BEVA, CETUX and PANIT in combination 
with or compared to fluoropyrimidine-based CT alone in 
patients with mCRC, through an updated systematic review 
and meta-analysis with prospective or retrospective obser-
vational cohort studies. We believe the updated review will 
help people better understand the benefits and harms of the 
different treatments in heterogeneous populations in the ‘real 
world,’ reflecting conditions in routine clinical practice [50, 
51]. This is important given the increasing costs of treat-
ments for cancer, increasing pressure on available resources 
[26, 27, 34, 52–54], and the extent of current litigation sur-
rounding these three MoAbs in Brazil.
2  Methods
This systematic review was based on the recommendations 
of the guidelines for Meta-analysis Of Observational Stud-
ies in Epidemiology (MOOSE) [55], with the protocol reg-
istered with the International Prospective Register of Sys-
tematic Reviews (PROSPERO) under no. CRD42016046613 
(http://www.crd.york.ac.uk/PROSP ERO).
2.1  Database and Search Strategy
The databases searched for potentially eligible studies 
included MEDLINE/PubMed (Medical Literature Analy-
sis and Retrieval System Online), LILACS (Latin Ameri-
can and Caribbean Health Science Literature), Cochrane 
Library, and EMBASE. All sources were searched until 
November 2017. We used various combinations of MeSH 
terms, including those relating to the disease, interventions, 
and study types (see the electronic supplementary mate-
rial, Table 1E). We supplemented this search with a manual 
search. In the manual search, we reviewed references in the 
annals of the Annual Meeting of the American Society of 
Clinical Oncology and the European Society for Medical 
Oncology between January 2014 and November 2017. In 
addition, we also manually searched the Journal of Clinical 
Oncology, the British Journal of Cancer, the Journal of the 
American Medical Association, and the World Journal of 
Gastroenterology, also for the period January 2014–Novem-
ber 2017.
We also searched the grey literature registered in the data 
bank of the Brazilian Digital Library of Theses and Dis-
sertations, the Digital Library of Theses and Dissertations 
of the University of São Paulo (USP), the Capes Theses 
Database, and the ProQuest Dissertation and Theses Data-
base, which included academic, government and conferences 
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publications, books and reports, and the Digital Library of 
Theses of the Federal University of Minas Gerais (UFMG).
2.2  Selection of Studies and Eligibility Criteria
We selected concurrent and non-concurrent observational 
studies of patients with mCRC. The studies compared the 
effectiveness and/or safety of BEVA, CETUX, and PANIT 
combined with FOLFIRI, FOLFOX, or fluorouracil, leucov-
orin and oxaliplatin (FLOX), or fluorouracil and leucovorin 
(5-FU/LV), or other combinations of fluoropyrimidine-based 
CT versus BEVA, CETUX, and PANIT, or any CT scheme 
including fluoropyrimidine-based CT alone in patients 
undergoing treatment.
The inclusion criteria included studies published in Portu-
guese, English or Spanish; patients aged 18 years and older 
of both sexes; stage IV mCRC; life expectancy > 3 months; 
and wild-type or mutant KRAS.
Studies were excluded if they compared doses, inter-
vention methods, or clinical protocols; were reviews, case 
reports, or studies in animals; were in vitro, pharmacody-
namic and/or pharmacokinetic studies; were genetic and/or 
genomic studies; investigated other types of cancer; assessed 
concomitant therapies with MoAbs other than BEVA, 
CETUX, and PANIT; and included participants under the 
age of 18 years, or those who had less than 3-months of 
follow-up.
2.3  Selection of Studies and Data Collection
The studies found in the electronic databases were collected 
into a single database  (EndNote® software) in order to delete 
duplicates. The selection and inclusion of studies were per-
formed in two stages by two pairs of independent review-
ers (WS and PA, JS and MS). This included the analysis 
of titles/abstracts followed by the full texts. Disagreements 
were resolved by a third reviewer (VA). The characteristics 
of the patients, their treatment length, as well as effective-
ness and safety data were retrieved and incorporated into an 
Excel spreadsheet designed for this purpose and previously 
tested.
2.4  Assessment of Methodological Quality 
of Included Studies
We used the Newcastle-Ottawa scale to assess the methodo-
logical quality of the observational studies [55, 56]. In this 
scale, each study is assessed in three dimensions: selection 
of the study groups; comparability of groups; and the cal-
culation of any exposure or outcomes of interest. The total 
score can be up to nine stars, and studies with a score above 
six are considered to be of high quality.
The sources of funding for the identified studies were 
examined for potential sources of bias. This is because the 
influence of this on subsequent findings has been seen in 
previously conducted reviews [57–59]. Comments regard-
ing any conflicts of interest (COI), the source of financing 
of the study, including whether funded by the manufac-
turer of any of the evaluated MoAbs, or whether any of 
the authors were related to the pharmaceutical industry, 
or received fees, were examined and documented. The 
possibility of publication bias was assessed using funnel 
plots [60] for the outcome if more than ten studies were 
involved.
2.5  Outcome Measures
The primary outcome measures considered were OS, PFS, 
and post-progression survival (PPS). The assessment of 
OS, measured by the time between diagnosis and death 
from any cause, is the most accepted method to assess the 
outcomes of cancer treatments, especially among payers of 
healthcare working with finite budgets in view of concerns 
linking PFS and other surrogate markers with OS in solid 
tumors [4, 24, 61–66]. American and European oncology 
groups also agree that OS should be the principal outcome 
measure in clinical studies [4, 62, 64], although PFS is 
also mentioned.
It is worth noting that PFS is used as a measure to assess 
a direct treatment effect on patients with metastatic can-
cer. However, PFS can be a concern when replacing OS, 
especially for funding decisions based on OS estimations 
in, for instance, cost/quality-adjusted life year calculations 
[67]. Having said this, PFS is validated and relevant to the 
patients. However, when used alone, it is not considered to 
be enough evidence of benefit to patients, which is exempli-
fied by recent guidance from the American Society of Clini-
cal Oncology [64]. For this reason, OS is recommended as 
a measure of effectiveness for new cancer medicines [65, 
68], with a significant effect on OS necessarily entailing a 
significant effect on PFS [66].
The secondary outcome measures were metastasectomy 
rates, response rates or disease control rate assessed by the 
Response Evaluation Criteria In Solid Tumors (RECIST) 
[69], and the occurrence of severe adverse events, consider-
ing only grade ≥ 3. The documentation of adverse events 
followed the Common Terminology Criteria for Adverse 
Events (CTCAE, version 4.0) of the National Institutes of 
Health (NIH) National Cancer Institute [70]. This describes 
and reports adverse events in a systematic way, providing a 
scale of severity for each adverse event ranging from grade 
1 up to grade 5, i.e., 1 = mild; 2 = moderate; 3 = severe; 
4 = extremely severe, life threatening; and 5 = death due to 
adverse events.
589Comparative Effectiveness/Safety of Monoclonal Antibodies in Combination with CT for mCRC 
2.6  Summary of Data and Statistical Analysis
The data from the studies were combined using the random 
effects model of the Review  Manager® software, version 
5.3. The results were presented by mean difference (MD) 
in months for continuous variables and expressed as rela-
tive risk for dichotomous variables, with a 95% confidence 
interval (CI). To estimate the magnitude of statistical incon-
sistency, we used the test I2 > 50% and a p value of < 0.10 
in the Chi-square test. Values above 75% were considered 
to have high heterogeneity [60]. A sensitivity analysis was 
conducted to assess the causes of heterogeneity, excluding 
one study at a time [60] and observing the changes in the I2 
and p values.
Due to the great variety of CT regimens based on fluoro-
pyrimidines, we chose to construct the grouping of the forest 
graph by the similarity of the treatments.
In cases where it was not possible to carry out the meta-
analysis, a qualitative synthesis of the studies was performed 
as the heterogeneity of the measurement instruments and the 
data did not allow for quantitative synthesis.
3  Results
3.1  Search Results and Included Studies
We found a total of 2363 publications in the electronic 
databases. After excluding duplicates, 2175 articles were 
selected for analysis of the titles and abstracts, and 269 for 
thorough reading. After a full analysis of the articles, 21 
studies were finally included in the meta-analysis (see the 
electronic supplementary material, Fig. 2E).
3.2  General Characteristics of the Studies Included 
in the Meta‑Analysis
The 21 observational studies that were included in the meta-
analysis were of the cohort type. Seventeen of them had a 
non-concurrent design and four a concurrent design. The 
follow-up time ranged from 6 to 37 months; however, this 
information was not reported in eight studies [69–76]. The 
duration of the studies ranged from 36 months (3 years) to 
132 months (11 years); however, no information was given 
in two studies [78, 79]. Eight studies declared COI, nine 
studies declared having no COI, and three studies did not 
provide this information. With respect to funding, seven 
studies did not mention the sources of funding [71, 72, 76, 
80–83], seven declared having been funded by the pharma-
ceutical industry [42, 73, 75, 78, 84–86], and the other stud-
ies were funded through other sources.
Nine studies assessed treatment with BEVA versus vari-
ous CT regimens including fluoropyrimidine-based CT 
(i.e., including FOLFIRI, FOLFOX, and FLOX), four stud-
ies assessed BEVA versus CETUX, and only two studies 
compared CETUX versus PANIT. Five studies assessed 
treatment with BEVA during maintenance therapy, i.e., no 
BEVA beyond disease progression (no BBP) (BEVA vs no 
BBP) (Table 1).
3.3  Methodological Quality
Among the studies assessed for methodological quality, two 
studies [42, 84] obtained the maximum score of nine stars 
using the Newcastle-Ottawa scale, three scored eight stars, 
seven scored seven stars, eight studies scored six, and one 
study scored five stars. As a result, the studies were seen 
overall as of moderate quality (Table 1). There was, though, 
asymmetry in the funnel plot for OS, suggesting publication 
bias (see the electronic supplementary material, Figs. 3E and 
4E).
3.4  Clinical Characteristics of the Patients 
in the Included Studies
To assess the comparative effectiveness and safety of the 
MoAbs (BEVA, CETUX, and PANIT) combined with CT 
or compared to only CT schemes, 10,180 participants were 
assessed in the 21 studies. The size of the studies ranged 
between 26 and 2526 patients.
With respect to the sociodemographic and clinical charac-
teristics of the patients in the studies, the patients’ mean ages 
ranged between 47 and 73 years and 40.5% were women. 
On average, according to data from five studies, 54% of the 
patients had exhibited wild-type KRAS and 45% unknown 
KRAS. In 14 of the studies, the primary location of the 
tumor was in the colon versus the rectum or other sites, and 
this was seen in 75% of patients. For lymph nodal metasta-
ses, only four studies presented data, and these metastases 
occurred in 32% of patients. According to data collected 
from six studies, the proportion of liver and lung metastases 
was 56% and 29%, respectively. Seven studies presented data 
for primary tumor removal, with 72.5% of the patients hav-
ing undergone resection of their primary tumor. Regarding 
the rate of disease control, five studies showed a 74% con-
trol rate, whereas, for progressive disease, this was 27% of 
patients according to the RECIST scale (Table 2).
3.5  Summary of the Data
BEVA was the most used MoAb in the largest number of 
studies that met the inclusion criteria. Due to the scarcity of 
comparative observational studies for PANIT and CETUX, 
we organized a comparison with a group called ‘with BEVA’ 
versus other therapeutic schemes that did not contain BEVA 
(no BEVA). From this group, we obtained five intervention 
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subgroups (Table  3), namely (a) BEVA + CT versus 
CT alone without specification of the combination; (b) 
BEVA + FOLFIRI versus FOLFIRI; (c) BEVA + FOLFOX 
versus FOLFOX; (d) BEVA + CT versus CETUX + CT; 
and (e) BEVA versus no BBP (without BEVA maintenance 
beyond progression and maintenance of some CT scheme). 
Two arms were built, i.e., BEVA versus no BEVA, since it 
was not possible to compare CETUX versus PANIT since 
there were concerns with the key measurements used. In 
addition to finding only two studies [12, 75] with this com-
parison, the authors used the median as a measure of central 
tendency. This is different from the other arms, where means 
were used for comparative purposes, making it difficult to 
include this arm in the analysis.
3.6  Primary Outcomes
OS and PFS had been assessed in all the intervention sub-
groups described, and PPS had been assessed in only one 
intervention subgroup (BEVA vs no BBP) [42, 73, 81, 84, 
85].
3.6.1  Overall Survival
We included 16 studies on OS, with 11,094 participants. 
There were significant differences between the groups 
BEVA versus no BEVA [13, 42, 71, 73, 74, 77, 78, 81–87] 
(MD = 4.07; 95% CI 1.69–6.45; p < 0.001; I2 = 81%). How-
ever, when we look at the clusters of CT regimens separately, 
we note the following: there were no statistically significant 
differences between the subgroups of BEVA + CT versus CT 
alone [13, 71, 78, 82] (MD = 2.83; 95% CI − 1.76 to 7.41; 
p = 0.23; I2 = 87%); BEVA + CT versus CETUX + CT [74, 
77, 86, 87] (MD = − 0.52; 95% CI − 7.7 to 6.67; p = 0.89; 
I2 = 0%) and BEVA + FOLFOX versus FOLFOX [13, 83] 
(MD = 8.63; 95% CI − 9.93 to 27.19; p = 0.36; I2 = 96%).
The subgroup BEVA + FOLFORI versus FOLFIRI [13] 
had been assessed in only one study, and the OS difference 
was not significant. The only significant differences were 
in the subgroups BEVA versus no BBP [42, 73, 81, 83, 85] 
(MD = 4.89; 95% CI 1.91–7.87; I2 = 73%), favoring BEVA 
(Table 3; Fig. 1).
We performed heterogeneity tests taking into consid-
eration the grouping of the CT regimens (or FOLFIRI or 
FOLFOX). We noticed that there was a difference when we 
removed the studies that used FOLFOX in association with 
BEVA. The heterogeneity was reduced from I2 = 81% to 
I2 = 68%. The withdrawal of the two studies (Suenaga et al. 
[83] and Meyerhardt et al. [13]) using FOLFOX as the asso-
ciated CT in the comparison arms with BEVA reduced the 
heterogeneity; however, this did not significantly change the 
outcome of this meta-analysis.
When we undertook sensitivity analysis with the exclu-
sion of the study by Grothey et al. [85], in the BEVA versus 
Table 3  Outcomes evaluated in the meta-analysis: BEVA vs schemes without BEVA (no BEVA)
I2 > 50% and a p value of the Chi-square test < 0.10 indicate significant heterogeneity between the studies
BEVA bevacizumab, CETUX cetuximab, CI confidence interval, CT chemotherapy, FOLFIRI folinic acid, 5-fluorouracil, irinotecan, FOLFOX 
folinic acid, 5-fluorouracil, oxaliplatin, I2 heterogeneity, NA not applicable, no BBP no bevacizumab beyond progression, RECIST Response 
Evaluation Criteria In Solid Tumors
Outcomes Studies n (references) Participants Estimated effect [95% CI] (pvalue) I2 (%) p value
Overall survival (months) 16 [13, 42, 71, 73, 74, 77, 78, 81–87] 11,094 4.07 [1.69 to 6.45] (p < 0.001) 81 0.00001
BEVA + CT vs CT alone 4 [13, 71, 78, 82] 4842 2.83 [− 1.76 to 7.41] (p = 0.23) 87 0.00001
BEVA + FOLFIRI vs FOLFIRI 1 [13] 267 2.20 [− 4.43 to 8.83] (p = 0.52) NA NA
BEVA + FOLFOX vs FOLFOX 2 [13, 83] 1885 8.63 [− 9.93 to 27.19] (p = 0.36) 96 0.00001
BEVA + CT vs CETUX + CT 4 [74, 77, 86, 87] 547 − 0.52 [− 7.71 to 6.67] (p = 0.89) 0 0.99
BEVA vs no BBP 5 [42, 73, 81, 84, 85] 3553 4.89 [1.91 to 7.87] (p = 0.001) 73 0.005
Progression-free survival 
(months)
11 [42, 71, 74, 76, 78, 81–83, 87, 88] 3704 2.85 [0.74 to 4.96] (p < 0.008) 90 0.00001
BEVA + CT vs CT alone 4 [71, 78, 82, 88] 2405 2.21 [− 0.06 to 4.48] (p = 0.06) 70 0.002
BEVA + FOLFORI vs FOLFIRI 1 [76] 35 8.60 [7.52 to 9.68] (p < 0.00001) NA NA
BEVA + FOLFOX vs FOLFOX 2 [76, 83] 247 3.72 [− 1.53 to 8.96] (p = 0.16) 95 0.0001
BEVA + CT vs CETUX + CT 2 [74, 87] 315 2.00 [0.33 to 3.67] (p = 0.04) 0 0.67
BEVA vs no BBP 2 [42, 81] 702 1.65 [− 3.74 to 7.03] (p = 0.55) 92 0.0003
Post-progression survival 
(months)
3 [73, 84, 85] 2851 5.90 [2.59 to 9.21] (p = 0.0005) 82 0.004
BEVA vs no BBP 3 [73, 84, 85] 2851 5.90 [2.59 to 9.21] (p = 0.0005) 82 0.004
Disease control rate (RECIST) 5 [74, 77, 80, 83, 88] 571 1.05 [0.98 to 1.12] (p = 0.45) 10 0.18
Metastasectomy rate (%) 2 [71, 77] 1897 2.01 [1.44 to 2.81] (p < 0.0001) 0 0.87
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no BBP grouping, we noticed that the reduction in the 
heterogeneity of this grouping was reduced from I2 = 73% 
to I2 = 0%. The general heterogeneity was reduced from 
I2 = 68% to I2 = 59%, and there was no change in the clinical 
outcome direction, with a statistically significant difference 
between the interventions (p < 0.00001)
3.6.2  Progression‑Free Survival
We included 11 studies on PFS with 3704 participants. 
There were significant differences between the groups 
BEVA versus no BEVA (MD = 2.85; 95% CI 0.74–4.96; 
p = 0.008; I2 = 94%). We performed the sensitivity analyses 
in the intervention subgroups because of the high statistical 
heterogeneity (I2 = 94%; p < 0.00001) (Table 3; Fig. 2).
In this analysis, the individual exclusion of studies of any 
intervention group neither reduced the high heterogeneity 
nor changed the outcome. However, the combined exclusion 
of studies, namely Hurwitz et al. [42] with BEVA versus 
no BEVA, Varol et al. [76] with BEVA + FOLFOX versus 
FOLFOX, Varol et al. [76] with BEVA + FOLFIRI versus 
FOLFIRI, and Turan et al. [82] on BEVA versus CT, showed 
MD = 3.30, 95% CI 2.17–4.42, p < 0.00001, and I2 = 0%.
3.6.3  Post‑Progression Survival
For PPS, we included three studies with 2851 participants. 
These three studies only assessed the effect of BEVA ver-
sus the no BBP intervention subgroup [73, 84, 85]. It was 
noted that the results of the meta-analysis demonstrated a 
significant benefit in PPS for patients treated with BEVA 
Fig. 1  Overall survival forest plot
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Fig. 2  Progression-free survival forest plot
Fig. 3  Post-progression survival forest plot
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(MD = 5.9; 95% CI 2.59–9.21; p = 0.0005) and high sta-
tistical heterogeneity (I2 = 82%; p = 0.004). In the sen-
sitivity analysis, the exclusion of the study conducted by 
Grothey et al. [84] indicated reduced heterogeneity (I2 = 0%; 
MD = 4.12; 95% CI 2.57–5.68; p < 0.00001) without chang-
ing the direction of the outcome (Table 3; Fig. 3).
3.7  Secondary Outcomes
For secondary outcomes, we analyzed 571 participants 
from five studies on the response rate or disease control rate 
measured by the RECIST scale [74, 77, 80, 82] and 1897 
participants from two studies regarding the metastasectomy 
rate [71, 77].
In the meta-analysis, we assessed eight studies that had 
described severe adverse events [72, 77, 83–85, 88, 89] for 
safety, including hypertension, arterial thromboembolism, 
venous thromboembolism, gastrointestinal perforation, 
bleeding, diarrhea, neutropenia, and other severe adverse 
events (Table 4).
The meta-analyses that assessed the disease control rate 
[74, 77, 80, 83, 90] did not show any statistically significant 
differences between BEVA and no BEVA interventions. The 
comparison revealed low heterogeneity (I2 = 10%; p = 0.18)
With respect to the metastasectomy rate [71, 77], 
there were statistically significant differences for BEVA 
(p < 0.0001) in comparison to no BEVA intervention. The 
meta-analysis showed no heterogeneity (Fig. 4).
Regarding adverse events, there were no statistically sig-
nificant differences between the interventions for arterial and 
venous thromboembolism, bleeding, diarrhea, neutropenia, 
and other severe adverse events (Table 4)
Table 4  Severe adverse events (grade ≥ 3)
CI confidence interval, GI gastrointestinal, I2 heterogeneity
Outcomes Studies n (references) Participants Estimated effect/[95% CI]/(p value) I2 (p value)
Hypertension 3 [76, 84, 85] 2436 1.36 [1.09–1.71] (p = 0.007) 2% (p = 0.36)
Arterial thromboembolism 4 [72, 81, 84, 85] 2948 0.89 [0.63–1.26] (p = 0.51) 0% (p = 0.81)
Venous thromboembolism 4 [13, 77, 81, 84] 4009 0.97 [0.82–1.13] (p = 0.66) 0% (p = 0.79)
GI Perforation 5 [13, 77, 81, 84, 85] 5182 1.89 [0.99–3.59] (p = 0.05) 17% (p = 0.31)
Bleeding 4 [77, 84, 85, 90] 2525 1.71 [0.80–3.65] (p = 0.17) 26% (p = 0.26)
Diarrhea 2 [77, 83] 371 0.63 [0.17–2.31] (p = 0.49) 0% (p = 0.49)
Neutropenia 2 [77, 83] 371 1.19 [0.90–1.58] (p = 0.22) 0% (p = 0.40)
Others events 4 [74, 83, 84, 90] 1565 1.27 [0.66–2.45] (p = 0.48) 8% (p = 0.35)
Fig. 4  Metastasectomy rate forest plot
Fig. 5  GI perforation forest plot. GI gastrointestinal
599Comparative Effectiveness/Safety of Monoclonal Antibodies in Combination with CT for mCRC 
With respect to gastrointestinal perforation (Fig. 5), we 
assessed five studies with 5182 participants. There was a 
borderline statistical difference, with a relative risk of 1.89, 
95% CI 0.99–3.59, p = 0.05, and I2 = 17%. We performed 
a sensitivity analysis excluding the study conducted by 
Grothey et al. [84]. We obtained a relative risk of 2.48 (95% 
CI 1.36–4.53), p = 0.003, and I2 = 0%, favoring the risk of 
an event occurring with BEVA.
There were statistically significant differences for hyper-
tension demonstrating the risk for this event with BEVA 
in comparison to no BEVA (p = 0.007). The meta-analysis 
indicated low heterogeneity (Fig. 6). Table 4 shows in detail 
the outcomes of severe adverse reactions comparing BEVA 
with no BEVA schemes.
3.8  Conflict of Interest
For the COI, we included nine studies with 8049 par-
ticipants. These nine studies evaluated the overall quality 
effect of the studies of the BEVA versus no BEVA [13, 
42, 71, 73, 74, 81, 83–85]. It was noted that the results 
of the meta-analysis demonstrated a significant differ-
ence in the COI subgroup for patients treated with BEVA 
(MD = 4.85; 95% CI 2.30–7.40; p = 0.0002) and high 
statistical heterogeneity (I2 = 74%, p = 0.004) (see the 
electronic supplementary material, Fig. 5E). The overall 
effect of the combined subgroups (COI and no COI) was 
also highly significant for patients treated with BEVA 
(p < 0.00001). Consequently, some of the studies may 
have been influenced by publication bias, as shown by 
funnel plots.
3.9  Quality of the Studies (Newcastle‑Ottawa Scale)
We included 19 studies with 9856 participants for BEVA 
versus no BEVA [13, 42, 71–74, 76–78, 80–87, 90]. There 
was a significant difference in the subgroup with a qual-
ity of seven or more stars for patients treated with BEVA 
(MD = 4.52; 95% CI 3.26–7.10; p < 0.00001) and a high sta-
tistical heterogeneity (I2 = 90%; p = 0.0001) (see the elec-
tronic supplementary material, Fig. 6E).
4  Discussion
Among the assessed MoAbs, BEVA had been assessed in 
the largest number of studies. The studies on effectiveness 
comparing BEVA and no BEVA groups demonstrated statis-
tically significant and clinically relevant benefits in patients 
treated with BEVA principally around OS, PFS, PPS and 
metastasectomy rates, but not in the disease control rate.
With respect to OS, patients given BEVA in combination 
with fluoropyrimidine-based CT regimens showed similar 
results across studies; however, better results (outcomes) 
were found when this comparison was made with patients 
who received BEVA versus CETUX. Analysis of the sub-
group of patients given maintenance of treatment with 
BEVA versus no BBP showed patients had better results 
with BEVA + CT compared to those when BEVA was sus-
pended and patients were maintained on CT alone (FOLFIRI 
or FOLFOX) when their disease progressed.
However, the effect on OS, PFS and PPS indicated sig-
nificant heterogeneity, which is probably attributable to dif-
ferences in the effects of BEVA therapy in combination with 
different CT regimens. One explanation for these findings 
is that studies tend to be more homogeneous when the same 
combinations of fluoropyrimidine-based CT regimens are 
used with each comparator arm. In the sensitivity analysis, 
studies that clearly used BEVA + FOLFOX versus FOLFOX 
(oxaliplatin-based) alone showed high heterogeneity. When 
these studies were excluded from the analysis, we observed a 
reduction in heterogeneity to acceptable levels without alter-
ing the clinical effects for the group.
However, in the PPS subgroup, this difference in timing 
of progression was statistically significant, and when the 
study of Grothey et al. [85] was excluded, a reduction of 
heterogeneity to I2 = 0% was observed.
The methodological quality of the various studies was 
moderate, with most studies funded by the pharmaceutical 
industry. This is important since previous meta-analyses 
conducted by our group and others have shown that stud-
ies funded by pharmaceutical companies tend to be more 
positive towards their medicines than those conducted by 
independent groups [57–59].
Fig. 6  Hypertension side effects forest plot
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In addition, high heterogeneity can also be attributed to 
the different treatment lines and different CT regimens asso-
ciated with anti-angiogenic therapy, anti-epidermal growth 
factor differences related to the KRAS status (wild type of 
mutation status), differences in prognostic factors such as 
performance status, location of the primary tumor, and the 
location of the metastases. Declared differences in COI and 
the quality of the studies can also be considered potential 
sources of heterogeneity. However, in all these cases, a sig-
nificant statistical heterogeneity of I2 > 75% can be expected.
The use of MoAbs as a therapeutic option for mCRC 
created expectations for greater OS, decreased toxicity 
and grade ≥ 3 adverse event complications compared with 
previous cytotoxic CT used in mCRC patients. Notably, it 
was observed that BEVA had been a milestone in clinical 
oncology [91]. However, in reality, there was only a modest 
impact on OS versus current CT regimens.
The results of this meta-analysis point to a statistically 
significant advantage in favor of BEVA. This advantage may 
be considered clinically modest in relation to a longer life 
for patients with metastatic disease; however, this should be 
considered a considerable advance in terms of the choices 
and options available for combinations of fluoropyrimidine-
based therapeutic regimens. The most important factor to 
note though is a statistically significant increase in severe 
adverse events associated with BEVA, especially severe 
hypertension and gastrointestinal perforation, which need 
to be factored into any decision.
Within Brazil, any modest improvement in effectiveness, 
coupled with a significant increase in severe adverse events 
with BEVA, needs to be balanced against the increasing 
number of successful litigations as well as the significant 
increase in costs and associated expenses with the MoAbs 
(Fig. 1E, electronic supplementary material). This reduces 
available resources for other priority disease areas; however, 
it increases the availability of these MoAb for diseases such 
as mCRC and cervical cancer, among others, which are not 
currently incorporated into the Brazilian health system. This 
raises the need for assessing their comparative effectiveness 
[51, 92] and as a therapeutic alternative capable of being 
incorporated into the Brazilian health system [93].
Our findings should also provide guidance to the judiciary 
when assessing potential funding decisions for these three 
MoAbs in patients with mCRC, similar to the situation with 
insulin glargine [54].
We did not find any previous systematic reviews assess-
ing the effectiveness and safety of the different MoAbs rel-
evant to the current situation. Some randomized studies had 
compared different treatment schemes combined or not with 
the MoAbs and showed conflicting results. Some studies 
indicated benefits, whereas others showed an increase in the 
toxicity profile of treatment without impacting on patients’ 
survival [94–99].
The result of this analysis demonstrated that the patients 
prescribed BEVA spend more time without disease pro-
gression and had a higher rate of resection compared to 
the non-BEVA or other anti-EGFR containing regimens, 
and there were significant gains in OS when re-analyzed 
to reduce the heterogeneity of the included studies. With 
respect to safety, most studies in the meta-analyses indi-
cated no significant reduction in severe adverse events 
using BEVA.
In a meta-analysis of Lv et al. [44], the efficacy and safety 
of adding BEVA to a therapy based on CETUX or PANIT 
for treating patients with mCRC were estimated. The authors 
suggested that the combination of anti-VEGF antibody 
(BEVA) and anti-EGFR antibody (CETUX and PANIT) 
had not improved PFS, OS, or the disease control rate when 
compared with the antibody alone. In addition, the incidence 
of grade ≥ 3 adverse events was not significantly greater in 
BEVA groups when compared to CETUX/PANIT groups. 
There are a number of similarities with our study findings.
On the other hand, the meta-analysis conducted by Wag-
ner et al. [47], which compared BEVA versus no BEVA as 
first-line CT, showed significant benefits in OS and PFS in 
patients treated with BEVA. We have previously pointed out 
that in the no BEVA group, in addition to the CT schemes, 
Wagner et al. [47] had used vatalanib (another VEGF inhibi-
tor), which was not included in our review.
We believe this situation justified the need for additional 
re-evaluation as more data became available. There was a 
high incidence of grade 3 and 4 adverse events for arterial 
hypertension, arterial thromboembolic events and gastroin-
testinal perforations in our review, which may compromise 
patient safety. Observational studies included in this analy-
sis, such as Meyerhardt et al. [88], Grothey et al. [84], and 
Yang et al. [77], agreed with the results found in the RCTs 
indicating the high patient risk of using BEVA. In the meta-
analysis conducted by Hapani et al. [43], the incidence of 
gastrointestinal perforation was 0.9% for patients receiving 
BEVA, with mortality at 21.7%.
Hurwitz et al. [100], comparing various CT schemes, 
combined or not with BEVA, as first- or second-line treat-
ment, found that the addition of BEVA was associated with 
a significant gain in OS and PFS defined by the CT back-
bone (oxaliplatin-based, irinotecan-based) and the extent of 
disease (liver metastases only, extensive disease), which is 
in accordance with the present study. The inclusion of more 
recent studies suggests an increase in OS, especially when 
reducing the heterogeneity of included studies. In addition, 
the incidence of grade ≥ 3 adverse events was higher in the 
group that received combinations with BEVA, confirming 
earlier studies.
With respect to safety, we emphasize that most outcomes 
of meta-analyses indicated no significant reduction in severe 
adverse events using BEVA. This implies that the promise 
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to use the MoAbs to reduce adverse events has not yet been 
fulfilled [43, 47].
In the studies reviewed and compared in our systematic 
review, there were some differences compared with individ-
ual studies. Individual studies indicated improvements with 
an average survival duration close to 3 years, and high sur-
vival rates at 5 years, which means an increase of 20% com-
pared to that seen in some trials with patients treated solely 
with CT [101]. However, for most patients, the improvement 
obtained with treatment would be palliative and not cura-
tive [102]. The main expectations are prolonging PPS and 
maintaining quality of life for as long as possible rather than 
improving OS.
It is important to recognize that mCRC is a chronic dis-
ease and that prolonging survival with CT regimens associ-
ated with biological agents is only typically seen for the PPS 
period, although there were modest improvements in OS 
with BEVA. However, it is necessary to evaluate the cost 
of new interventions according to the configuration of each 
health system and their associated costs for reimbursement 
and funding decisions. Marginal gains for high-cost medi-
cines are not seen as acceptable if this restricts funding for 
other more effective interventions in this and other patient 
populations within health systems with universal access. 
This may well mean denying effective treatment options in 
other high-priority disease areas, which is increasingly dif-
ficult to justify within finite budgets [28, 61, 103]. However, 
it is important to note that advances made in first-line treat-
ment will also be applied to the second-line treatment [4].
In addition, assessments of adverse events have typically 
only been carried out for severe cases. In our review, we did 
not assess the effect that adverse events have on patients’ 
quality of life, i.e., BEVA-induced dysphonia (necrosis of 
the vocal cords) and hearing loss due to BEVA, given that 
they were not life threatening.
Another important finding was the COI seen in some of 
the studies, which Thompson and others [104, 105] con-
sider to be a set of study conditions in which professional 
judgment could be unduly influenced by interests such as 
financial gain. Scientific publications that present a COI with 
pharmaceutical companies can be a concern as they can be 
persuasive and avoid disclosing negative results, more fre-
quently have favorable results towards the sponsor’s medi-
cine, or even influence the delay in disclosing these results 
as a strategy to protect potential markets [106–110]. Some of 
the findings in the studies selected in this systematic review 
and meta-analysis may have been influenced by publication 
bias, as shown by funnel plots (see the electronic supplemen-
tary material, Figs. 3E.1 and 4E.2) as well as Fig. 5E, with 
the subgroups combined (COI and no COI) favoring patients 
treated with BEVA (p < 0.00001).
We also performed a meta-analysis to evaluate the quality 
of non-randomized studies, based on the quality assessment 
guideline made by the MOOSE tool, using the Newcastle-
Ottawa scale. Low-quality studies may lead to a distortion of 
the summary of effect estimation (see the electronic supple-
mentary material, Fig. 6E). Our findings show that there is a 
statistically significant difference between studies that were 
rated six stars or less and those rated seven stars or higher. 
Consequently, the high heterogeneity among the studies in 
this meta-analysis may be influenced proportionally by the 
quality of the studies.
We recognize this systematic review has some limita-
tions. We only included observational studies, and the bias 
of this study design is its lack of randomization as well as 
uncontrolled confounding factors. Some studies did not pro-
vide complete and/or accurate information, excluding them 
from the quantitative analysis; consequently, hindering the 
understanding of the heterogeneity found in some compari-
son groups. In addition, only five studies assessed the effect 
of discontinuing BEVA beyond disease progression, and 
most of the studies did not use the same combinations or 
treatment schemes, although 16 of the 21 studies had used a 
CT scheme combined with fluorouracil.
Therapeutic care (in terms of the types of interventions, 
therapeutic schemes, and the level of expertise) was also 
rarely described in detail in these studies.
However, despite these limitations, we believe that our 
findings are robust in view of our methodological approach. 
This was confirmed by the sensitivity analysis where the 
inclusion and exclusion of studies in each comparison did 
not change the direction of most outcomes; however, signifi-
cant changes were observed in heterogeneity.
5  Conclusions
The results of this meta-analysis point to a statistically sig-
nificant advantage in favor of BEVA for the outcomes of 
OS, PFS, PPS, and the metastasectomy rate. This advan-
tage may be considered clinically modest in relation to the 
patient’s lifetime in the metastatic stage. This increases the 
choices for combining BEVA with fluoropyrimidine-based 
regimens, but we must not overlook the quality of life of 
these patients. This is because one of the most important fac-
tors to be observed with BEVA is the statistically significant 
increase in adverse events associated with its use, especially 
severe hypertension and gastrointestinal perforation.
This review also emphasized that studies directly compar-
ing the effectiveness and safety of MoAbs in patients with 
mCRC are currently scarce, which needs to be addressed 
when payers are faced with funding choices. There is also 
a need for further observational studies to assess OS and 
adverse events comparing MoAbs associated with the dif-
ferent CT regimens given current concerns with their impact 
on OS in reality.
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These findings combined with those from RCTs can be 
used to update clinical guidelines to systematically promote 
better and more appropriate healthcare within universal 
healthcare systems through establishing the magnitude 
of benefits, risks, and costs, relating to specific aspects of 
patient care. In addition, it is hoped this review will also be 
of interest to the judiciary when authorizing resources for 
high-cost medicines with limited benefits, as this means less 
funds are available for valuable medicines in other priority 
areas.
Compliance with Ethical Standards 
Funding The research was supported by the Research Group on Phar-
macoepidemiology (GPFE), Centro Colaborador do SUS (CCATES) 
and Research Group on Health Economics (GPES) of UFMG. This 
systematic review is an integral part of the research project “Economic 
evaluation of monoclonal antibody treatments in metastatic colorectal 
cancer,” with financial support from the National Council for Scien-
tific and Technological Development (CNPq), the Minas Gerais State 
Agency for Research and Development (FAPEMIG) and the Coordina-
tion for the Improvement of Higher Education Personnel (CAPES).
Conflict of interest Wânia Cristina da Silva, Vânia Eloisa de Araujo, 
Ellias Magalhães e Abreu Lima, Jessica Barreto Ribeiro dos Santos, 
Michael Ruberson Ribeiro da Silva, Paulo Henrique Ribeiro Fernandes 
Almeida, Francisco de Assis Acurcio, Brian Godman, Amanj Kurdi, 
Mariângela Leal Cherchiglia, and Eli Iola Gurgel Andrade declare that 
they have no conflicts of interest that might influence the results of the 
investigation.
Data availability All the papers incorporated into this systematic 
review and meta-analysis have been fully referenced.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution-NonCommercial 4.0 International License 
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any 
noncommercial use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate 
if changes were made.
References
 1. Ellen ’t Hoen L. Access to cancer treatment: a study of medicine 
pricing issues with recommendations for improving access to 
cancer medication [Internet]. World Health Organization. 2014 
[cited 2018 Jan]. Available from: http://apps.who.int/medic inedo 
cs/en/d/Js217 58en/.
 2. WHO | Cancer. 2018 Jan 30 [cited 2018 Jan 31]; Available from: 
http://www.who.int/cance r/en/.
 3. IARC. GLOBOCAN—Estimated colorectal cancer mortal-
ity worldwide in 2012 [Internet]. GLOBOCAN. 2012. Avail-
able from: http://globo can.iarc.fr/Pages /fact_sheet s_cance 
r.aspx?cance r=color ectal .
 4. Noonan AM, Bekaii-Saab T. Second-line outcomes in metastatic 
colorectal cancer—raising the bar for the high jump rather than 
the doing the limbo. Expert Rev Pharmacoecon Outcomes Res 
[Internet]. 2014;15(1):133–43. Available from: http://dx.doi.
org/10.1586/14737 167.2015.97237 6.
 5. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, ESMO 
Guidelines Working Group. Metastatic colorectal cancer: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-
up. Ann Oncol [Internet]. 2014;25(Suppl 3):iii1–9. Available 
from: http://dx.doi.org/10.1093/annon c/mdu26 0.
 6. Cordeiro F. Diretrizes para diagnóstico, estadiamento e trata-
mento cirúrgico e multidisciplinar do câncer colorretal. Revista 
da Associação Médica Brasileira [Internet]. 2004;50(1):10–1. 
Available from: http://dx.doi.org/10.1590/s0104 -42302 00400 
01000 17.
 7. University of Luxembourg. “New biomarkers for colorec-
tal cancer.” ScienceDaily. www.scien cedai ly.com/relea 
ses/2018/01/18011 11014 19.htm. Accessed 6 Apr 2018.
 8. Wardle J, Robb K, Vernon S, Waller J. Screening for prevention 
and early diagnosis of cancer. Am Psychol. 2015;70:119–33.
 9. Mitry E, Fields ALA, Bleiberg H, Labianca R, Portier G, Tu D, 
et al. Adjuvant chemotherapy after potentially curative resection 
of metastases from colorectal cancer: a pooled analysis of two 
randomized trials. J Clin Oncol [Internet]. 2008;26(30):4906–11. 
Available from: http://dx.doi.org/10.1200/JCO.2008.17.3781.
 10. Rougier P, Mitry E. Cancers colorectaux avant et après les bio-
thérapies : une révolution dans la prise en charge des patients ? 
Gastroentérologie Clinique et Biologique [Internet]. 2009;33(8–
9):672–80. Available from: http://dx.doi.org/10.1016/j.
gcb.2009.07.019.
 11. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, 
Cassidy J, et al. Leucovorin and fluorouracil with or without 
oxaliplatin as first-line treatment in advanced colorectal cancer. 
J Clin Oncol [Internet]. 2000;18(16):2938–47. Available from: 
http://dx.doi.org/10.1200/jco.2000.18.16.2938.
 12. Yamaguchi T, Iwasa S, Nagashima K, Ikezawa N, Hamaguchi 
T, Shoji H, et al. Comparison of panitumumab plus irinotecan 
and cetuximab plus irinotecan for KRAS wild-type metastatic 
colorectal cancer. Anticancer Res [Internet]. 2016;36(7):3531–6. 
Available from: https ://www.ncbi.nlm.nih.gov/pubme d/27354 
619.
 13. Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effec-
tiveness of bevacizumab with first-line combination chemo-
therapy for medicare patients with stage IV colorectal cancer. J 
Clin Oncol [Internet]. 2012;30(6):608–15. Available from: http://
dx.doi.org/10.1200/jco.2011.38.9650.
 14. Tournigand C, Bengrine-Lefevre L. Quelles nouvelles stratégies 
dans le traitement du cancer colorectal métastatique avec les bio-
thérapies ? Rev Med Interne [Internet]. 2009;30(5):411–5. Avail-
able from: http://dx.doi.org/10.1016/j.revme d.2008.12.015.
 15. National Comprehensive Cancer  Network®  (NCCN®). NCCN 
Guidelines for  Patients®: colon cancer, version 1. 2016. Avail-
able from: https ://books .googl e.com/books /about /NCCN_Guide 
lines _for_Patie nts.html?hl=&id=BLPuv QAACA AJ.
 16. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an 
affordable price: engaging stakeholders in cancer care. Lancet 
Oncol. 2014;15(3):e112–8.
 17. Prasad V, Wang R, Afifi SH, Mailankody S. The rising price of 
cancer drugs—a new old problem? JAMA Oncol. 2017;3(2):277.
 18. Editorial. The price of drugs for chronic myeloid leukemia 
(CML) is a reflection of the unsustainable prices of cancer drugs: 
from the perspective of a large group of CML experts. Blood. 
2013;121(22):4439–42.
 19. Fojo T, Lo AW. Price, value, and the cost of cancer drugs. Lancet 
Oncol. 2016;17:3–5.
 20. Goldstein DA, Clark J, Tu Y, Zhang J, Fang F, Goldstein R, et al. 
A global comparison of the cost of patented cancer drugs in 
relation to global differences in wealth. Oncotarget. 2017;8(42). 
Available from: http://dx.doi.org/10.18632 /oncot arget .17742 .
603Comparative Effectiveness/Safety of Monoclonal Antibodies in Combination with CT for mCRC 
 21. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the mar-
ket for anticancer drugs. J Econ Perspect. 2015;29(1):139–62.
 22. Ghinea H, Kerridge I, Lipworth W. If we don’t talk about value, 
cancer drugs will become terminal for health systems. The Con-
versation. 2015. Available from:https ://ses.libra ry.usyd.edu.au/
bitst ream/2123/13653 /2/TheCo nv_if-we-dont-talk-about -value 
-2015.pdf.
 23. Chalkidou K, Marquez P, Dhillon PK, Teerawattananon Y, 
Anothaisintawee T, Gadelha CA, et al. Evidence-informed 
frameworks for cost-effective cancer care and prevention 
in low, middle, and high-income countries. Lancet Oncol. 
2014;15(3):e119–31.
 24. Konda B, Shum H, Rajdev L. Anti-angiogenic agents in meta-
static colorectal cancer. World J Gastrointest Oncol [Internet]. 
2015;7(7):71–86. Available from: http://dx.doi.org/10.4251/
wjgo.v7.i7.71.
 25. Noonan AM, Bekaii-Saab T. Second-line outcomes in met-
astatic colorectal cancer—raising the bar for the high jump 
rather than the doing the limbo. Expert Rev Pharmacoecon 
Outcomes Res [Internet]. 2014;15(1):133–43. Available from: 
http://dx.doi.org/10.1586/14737 167.2015.97237 6.
 26. Fojo T, Grady C. How much is life worth: cetuximab, non-
small cell lung cancer, and the $440 billion question. J Natl 
Cancer Inst. 2009;101:1044–8.
 27. Godman B, Wild C, Haycox A. Patent expiry and costs for anti-
cancer medicines for clinical use. Generics Biosimilars Initiat 
J [Internet]. 2017;6(3):105–6. Available from: http://dx.doi.
org/10.5639/gabij .2017.0603.021.
 28. Haycox  A.  Why  cance r?  Pha r macoEconomics . 
2016;34(7):625–7.
 29. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison 
CT, Wu S, et al. Expression of epiregulin and amphiregulin 
and K-ras mutation status predict disease control in metastatic 
colorectal cancer patients treated with cetuximab. J Clin Oncol 
[Internet]. 2007;25(22):3230–7. Available from: http://dx.doi.
org/10.1200/JCO.2006.10.5437.
 30. Raskov H, Pommergaard H-C, Burcharth J, Rosenberg J. Colo-
rectal carcinogenesis—update and perspectives. World J Gas-
troenterol [Internet]. 2014;20(48):18151–64. Available from: 
http://dx.doi.org/10.3748/wjg.v20.i48.18151 .
 31. Hsu H-C, Thiam TK, Lu Y-J, Yeh CY, Tsai W-S, You JF, 
et al. Mutations of KRAS/NRAS/BRAF predict cetuximab 
resistance in metastatic colorectal cancer patients. Oncotarget 
[Internet]. 2016;7(16):22257–70. Available from: http://dx.doi.
org/10.18632 /oncot arget .8076.
 32. Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis 
of KRAS testing and cetuximab as last-line therapy for colo-
rectal cancer. Mol Diagn Ther [Internet]. 2010;14(6):375–84. 
Available from: http://dx.doi.org/10.2165/11587 610-00000 
0000-00000 .
 33. Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, 
Goldberg RM. Cost-effectiveness of KRAS testing in metastatic 
colorectal cancer patients in the United States and Germany. Int 
J Cancer [Internet]. 2012;131(2):438–45. Available from: http://
dx.doi.org/10.1002/ijc.26400 .
 34. Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutié-
rrez-Ibarluzea I, Jones J, et al. Personalizing health care: feasibil-
ity and future implications. BMC Med [Internet]. 2013;11:179. 
Available from: http://dx.doi.org/10.1186/1741-7015-11-179.
 35. SMC-SCOTTISH MEDICINES. [cited 2018 Mar 6]. Avail-
able from: https ://www.scott ishme dicin es.org.uk/SMC_Advic 
e/Advic e/Bevac izuma b__Avast in__174___for_first line_treat 
ment_of_patie nts_with_metas tatic _cance r_of_the_colon _or_
rectu m/Bevac izuma b_100mg _4ml_and_400mg _16ml_solut 
ion_for_intra venou s_infus ion__Avast in.
 36. Scotland N. Bevacizumab  (Avastin®) for first-line treatment of 
patients with metastatic cancer of the colon or rectum [Inter-
net]. Scottish Medicines Consortium (SMC). 2006 [cited FEV 
2018]. Available from: https ://www.scott ishme dicin es.org.uk/
SMC_Advic e/Advic e/Bevac izuma b__Avast in__174___for_first 
-line_treat ment_of_patie nts_with_metas tatic _cance r_of_the_
colon _or_rectu m.
 37. NICE-Bevacizumab and cetuximab for the treatment of meta-
static colorectal cancer | Guidance and guidelines | NICE. [cited 
2018 Mar 6]; Available from: https ://www.nice.org.uk/guida nce/
ta118 .
 38. Australian Government Department of Health. [cited 2018 
Mar 6]. Available from: http://searc h.healt h.gov.au/s/searc 
h.html?query =Bevac izuma b&colle ction =healt h&profi le.
 39. Australian Government Department of Health. Bevacizumab, 
solution for IV use. PBS—The Pharmaceutical Benefits Scheme 
[Internet]. Australia’s Pharmaceutical Benefits Scheme (PBS). 
2013 [cited Fev 2018]. Available from: http://www.pbs.gov.au/
info/indus try/listi ng/eleme nts/pbac-meeti ngs/psd/2013-11/bevac 
izuma b.
 40. Bevacizumab for advanced colorectal cancer | CADTH.ca [Inter-
net]. [cited 2018 Mar 6]. Available from: https ://www.cadth .ca/
bevac izuma b-advan ced-color ectal -cance r-0.
 41. Cetuximab, bevacizumab and panitumumab for the treatment of 
metastatic colorectal cancer after first-line chemotherapy: cetuxi-
mab (monotherapy or combination chemotherapy), bevacizumab 
(in combination with non-oxaliplatin chemotherapy) and panitu-
mumab (monotherapy) for the treatment of metastatic colorectal 
cancer after first-line chemotherapy | Guidance and guidelines 
| NICE. [cited 2018 Mar 6]; Available from: https ://www.nice.
org.uk/guida nce/ta242 .
 42. Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, 
Roach N, et al. Safety and effectiveness of bevacizumab treat-
ment for metastatic colorectal cancer: final results from the 
Avastin(®) Registry—Investigation of Effectiveness and Safety 
(ARIES) observational cohort study. Clin Oncol [Internet]. 
2014;26(6):323–32. Available from: http://dx.doi.org/10.1016/j.
clon.2014.03.001.
 43. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in 
patients with cancer treated with bevacizumab: a meta-analysis. 
Lancet Oncol [Internet]. 2009;10(6):559–68. Available from: 
http://dx.doi.org/10.1016/S1470 -2045(09)70112 -3.
 44. Lv Y, Yang Z, Zhao L, Zhao S, Han J, Zheng L. The efficacy and 
safety of adding bevacizumab to cetuximab- or panitumumab-
based therapy in the treatment of patients with metastatic colo-
rectal cancer (mCRC): a meta-analysis from randomized control 
trials. Int J Clin Exp Med [Internet]. 2015;8(1):334–45. Available 
from: https ://www.ncbi.nlm.nih.gov/pubme d/25785 004.
 45. Rosa B, de Jesus JP, de Mello EL, Cesar D, Correia MM. Effec-
tiveness and safety of monoclonal antibodies for metastatic colo-
rectal cancer treatment: systematic review and meta-analysis. 
Ecancermedicalscience [Internet]. 2015;9:582. Available from: 
http://dx.doi.org/10.3332/ecanc er.2015.582.
 46. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical 
benefit of bevacizumab in metastatic colorectal cancer is inde-
pendent of K-ras mutation status: analysis of a phase III study of 
bevacizumab with chemotherapy in previously untreated meta-
static colorectal cancer. Oncologist [Internet]. 2009;14(1):22–
8. Available from: http://dx.doi.org/10.1634/theon colog 
ist.2008-0213.
 47. Wagner ADA, Arnold D, Grothey AAG, Haerting J, Unverzagt 
S. Anti-angiogenic therapies for metastatic colorectal cancer. 
Cochrane Database Syst Rev [Internet]. 2009; Available from: 
http://dx.doi.org/10.1002/14651 858.cd005 392.pub3.
 48. CONITEC. Cetuximabe para o tratamento do câncer color-
retal- Comissão Nacional de Incorporação de Tecnologias no 
604 W. C. da Silva et al.
SUS—CONITEC [Internet]. CONITEC—Comissão Nacional 
de Incorporação de Tecnologias no SUS. 2017 [cited 2018 Jan]. 
Available from: http://conit ec.gov.br/image s/Relat orios /2017/
Relat orio_Cetux imabe _cance r_color retal _metas tatic o_.
 49. CMED- Listas de preços de medicamentos - ANVISA [Internet]. 
[cited 2018 Mar 6]. Available from: http://porta l.anvis a.gov.br/
lista s-de-preco s.
 50. Giordano SH. Comparative effectiveness research in cancer with 
observational data. Am Soc Clin Oncol Educ Book [Internet]. 
2015;e330–5. Available from: http://dx.doi.org/10.14694 /EdBoo 
k_AM.2015.35.e330.
 51. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, 
Gliklich R. Why observational studies should be among the 
tools used in comparative effectiveness research. Health Aff 
[Internet]. 2010;29(10):1818–25. Available from: http://dx.doi.
org/10.1377/hltha ff.2010.0666.
 52. Ma CKK, Danta M, Day R, Ma DDF. Dealing with the spi-
ralling price of medicines: issues and solutions. Intern Med 
J [Internet]. 2018;48(1):16–24. Available from: http://dx.doi.
org/10.1111/imj.13652 .
 53. Barron A, Wilsdon T. Challenging perceptions about oncol-
ogy product pricing in breast and colorectal cancer. Pharma-
ceut Med [Internet]. 2016;30(6):321–6. Available from: http://
dx.doi.org/10.1007/s4029 0-016-0167-1.
 54. Caires de Souza AL, de Souza ALC, de Assis Acurcio F, Júnior 
AAG, do Nascimento RCRM, Godman B, et al. Insulin glar-
gine in a Brazilian state: should the government disinvest? An 
assessment based on a systematic review. Appl Health Econ 
Health Policy [Internet]. 2014;12(1):19–32. Available from: 
http://dx.doi.org/10.1007/s4025 8-013-0073-6.
 55. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, 
Rennie D, et al. Meta-analysis of observational studies in epi-
demiology: a proposal for reporting. Meta-analysis Of Obser-
vational Studies in Epidemiology (MOOSE) group. JAMA 
[Internet]. 2000;283(15):2008–12. Available from: https ://
www.ncbi.nlm.nih.gov/pubme d/10789 670.
 56. Hartling L, Hamm M, Milne A, Vandermeer B, Santaguida 
PL, Ansari M, et al. Validity and inter-rater reliability testing 
of quality assessment instruments [Internet]. Rockville (MD): 
Agency for Healthcare Research and Quality (US); 2012. 
Available from: https ://www.ncbi.nlm.nih.gov/pubme d/22536 
612.
 57. Marra LP, Araújo VE, Silva TBC, Diniz LM, Guerra Junior AA, 
Acurcio FA, et al. Clinical effectiveness and safety of analog 
glargine in type 1 diabetes: a systematic review and meta-analy-
sis. Diabetes Ther [Internet]. 2016;7(2):241–58. Available from: 
http://dx.doi.org/10.1007/s1330 0-016-0166-y.
 58. Almeida PHRF, Silva TBC, de Assis Acurcio F, Guerra Júnior 
AA, Araújo VE, Diniz LM, et al. Quality of life of patients with 
type 1 diabetes mellitus using insulin analog glargine compared 
with NPH insulin: a systematic review and policy implica-
tions. Patient [Internet]. 2018 ; Available from: http://dx.doi.
org/10.1007/s4027 1-017-0291-3.
 59. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. 
Why olanzapine beats risperidone, risperidone beats quetiapine, 
and quetiapine beats olanzapine: an exploratory analysis of head-
to-head comparison studies of second-generation antipsychotics. 
Am J Psychiatry. 2006;163:185–94.
 60. Higgins JPT, Green S. Cochrane Handbook for System-
atic Reviews of Interventions [Internet]. John Wiley & Sons; 
2011. p. 672. Available from: https ://marke t.andro id.com/detai 
ls?id=book-NKMg9 sMM6G UC.
 61. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs 
in the United States: Justum Pretium–the just price. J Clin Oncol. 
2013;31(28):3600–4.
 62. Wild C, Grössmann N, Bonanno PV, Bucsics A, Furst J, Garu-
oliene K, et al. Utilisation of the ESMO-MCBS in practice of 
HTA. Ann Oncol [Internet]. 2016;27(11):2134–6. Available 
from: http://dx.doi.org/10.1093/annon c/mdw29 7.
 63. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark 
N, et al. Pathological complete response and long-term clinical 
benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 
[Internet]. 2014 Jul 12;384(9938):164–72. Available from: http://
dx.doi.org/10.1016/S0140 -6736(13)62422 -8.
 64. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cor-
tazar P, et al. American Society of Clinical Oncology perspec-
tive: raising the bar for clinical trials by defining clinically mean-
ingful outcomes. J Clin Oncol [Internet]. 2014;32(12):1277–80. 
Available from: http://dx.doi.org/10.1200/jco.2013.53.8009.
 65. Ferguson JS, Summerhayes M, Masters S, Schey S, Smith IE. 
New treatments for advanced cancer: an approach to prioritiza-
tion. Br J Cancer. 2000;83(10):1268–73.
 66. Gyawali B, Hey S, Kesselheim AS. A comparison of response 
patterns for progression-free survival and overall survival follow-
ing treatment for cancer with pd-1 inhibitors: a meta-analysis of 
correlation and differences in effect sizes. JAMA Netw Open. 
2018;1(2):e180416.
 67. Paris V. Belloni A. Value in pharmaceutical pricing. Available 
at: http://www.oecd-ilibr ary.org/socia l-issue s-migra tion-healt 
h/value -in-pharm aceut ical-prici ng_5k43j c9v6k nx-en. OECD 
Health Working Papers. https ://doi.org/10.1787/5k43j c9v6k 
nx-en.
 68. Henshall CSL, Eichler H-G, Lemgruber A, Longson C, O’Rourke 
B, Tunis S. Understanding the role and evidence expectations of 
health technology assessment and coverage/payer bodies: what 
are they looking for, and how and why does this differ from what 
regulators require? Ther Innov Regul Sci. 2013;48(3):341–6.
 69. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, 
Rubinstein L, et al. New guidelines to evaluate the response to 
treatment in solid tumors. European Organization for Research 
and Treatment of Cancer, National Cancer Institute of the United 
States, National Cancer Institute of Canada. J Natl Cancer Inst 
[Internet]. 2000;92(3):205–16. Available from: https ://www.ncbi.
nlm.nih.gov/pubme d/10655 437.
 70. NIH. Common Terminology Criteria for Adverse Events 
(CTCAE), NIH publication [Internet]. NIH-National Can-
cer Institute. 2010 [cited 2018 Jan]. Available from: https ://
wiki.nci.nih.gov/displ ay/VKC/Commo n+Termi nolog y+Crite 
ria+for+Adver se+Event s+FAQ.
 71. Hammerman A, Greenberg-Dotan S, Battat E, Feldhamer I, Bit-
terman H, Brenner B. The “real-life” impact of adding beva-
cizumab to first-line therapy in metastatic colorectal cancer 
patients: a large Israeli retrospective cohort study. Acta Oncol 
[Internet]. 2014;54(2):164–70. Available from: http://dx.doi.
org/10.3109/02841 86x.2014.95853 2.
 72. Al-Shamsi HO, Anjum M, Al Farsi A, Shen H, Linkins L-A, 
Cook RJ, et al. Thrombotic events in patients with metastatic 
colorectal cancer treated with FOLFIRI plus bevacizumab. J Clin 
Oncol [Internet]. 2013;31(4_suppl):540–540. Available from: 
http://dx.doi.org/10.1200/jco.2013.31.4_suppl .540.
 73. Cartwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth 
M. Survival outcomes of bevacizumab beyond progression in 
metastatic colorectal cancer patients treated in US community 
oncology. Clin Colorectal Cancer [Internet]. 2012;11(4):238–46. 
Available from: http://dx.doi.org/10.1016/j.clcc.2012.05.005.
 74. Deng Y, Cai Y, Lin J, Jiang L, Hu H. Survival of patients with 
KRAS wild-type metastatic colorectal cancer is identical after 
sequential treatment with cetuximab and bevacizumab regardless 
of the sequence—a retrospective single-center study. Gastroen-
terol Rep [Internet]. 2015;3(4):339–43. Available from: http://
dx.doi.org/10.1093/gastr o/gov05 1.
605Comparative Effectiveness/Safety of Monoclonal Antibodies in Combination with CT for mCRC 
 75. Dotan E, Devarajan K, James D’Silva A, Beck A, Kloth DD, 
Cohen SJ, et al. Patterns of use and tolerance of anti-epider-
mal growth factor receptor antibodies in older adults with 
metastatic colorectal cancer. Clin Colorectal Cancer [Internet]. 
2014;13(3):192–8. Available from: http://dx.doi.org/10.1016/j.
clcc.2014.05.003.
 76. Varol U, Karaca B, Cakar B, Sezgin C, Karabulut B, Uslu R. 
Comparing time to disease progression of irinotecan and oxalipl-
atin-based chemotherapies in colorectal cancer patients with liver 
only metastasis. Am J Clin Oncol [Internet]. 2013;36(4):388–91. 
Available from: http://dx.doi.org/10.1097/coc.0b013 e3182 48da7 
c.
 77. Yang Y-H, Lin J-K, Chen W-S, Lin T-C, Yang S-H, Jiang 
J-K, et al. Comparison of cetuximab to bevacizumab as the 
first-line bio-chemotherapy for patients with metastatic colo-
rectal cancer: superior progression-free survival is restricted 
to patients with measurable tumors and objective tumor 
response–a retrospective study. J Cancer Res Clin Oncol [Inter-
net]. 2014;140(11):1927–36. Available from: http://dx.doi.
org/10.1007/s0043 2-014-1741-0.
 78. Houts AC, Ogale S, Zafar Y, Hubbard JM, Satram-Hoang S, 
Sommer N, et al. Progression-free survival in patients receiv-
ing chemotherapy alone (C) or chemotherapy with bevaci-
zumab (CB) for first-line treatment of KRAS mutant metastatic 
colorectal cancer in community oncology settings. J Gastro-
intest Cancer [Internet]. 2017; Available from: http://dx.doi.
org/10.1007/s1202 9-017-0017-8.
 79. Chung W-S, Park M-S, Shin SJ, Baek S-E, Kim Y-E, Choi 
JY, et al. Response evaluation in patients with colorectal liver 
metastases: RECIST version 1.1 versus modified CT criteria. 
AJR Am J Roentgenol [Internet]. 2012;199(4):809–15. Avail-
able from: http://dx.doi.org/10.2214/AJR.11.7910.
 80. Pietrantonio F, Mazzaferro V, Miceli R, Cotsoglou C, Melotti 
F, Fanetti G, et al. Pathological response after neoadjuvant 
bevacizumab- or cetuximab-based chemotherapy in resected 
colorectal cancer liver metastases. Med Oncol [Internet]. 
2015;32(7):182. Available from: http://dx.doi.org/10.1007/
s1203 2-015-0638-3.
 81. Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi 
E, et al. Maintenance single-agent bevacizumab or observation 
after first-line chemotherapy in patients with metastatic colorec-
tal cancer: a multicenter retrospective study. Invest New Drugs 
[Internet]. 2013;31(4):1035–43. Available from: http://dx.doi.
org/10.1007/s1063 7-013-9936-9.
 82. Turan N, Benekli M, Dane F, Unal OU, Kara HV, Koca D, et al. 
Adjuvant systemic chemotherapy with or without bevacizumab 
in patients with resected pulmonary metastases from colorectal 
cancer. Thoracic Cancer [Internet]. 2014;5(5):398–404. Avail-
able from: http://dx.doi.org/10.1111/1759-7714.12107 .
 83. Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ueno M, 
Yamaguchi T. Retrospective analysis on the efficacy of beva-
cizumab with FOLFOX as a first-line treatment in Japanese 
patients with metastatic colorectal cancer. Asia Pac J Clin Oncol 
[Internet]. 2014;10(4):322–9. Available from: http://dx.doi.
org/10.1111/ajco.12094 .
 84. Grothey A, Flick ED, Cohn AL, Bekaii-Saab TS, Bendell JC, 
Kozloff M, et al. Bevacizumab exposure beyond first disease pro-
gression in patients with metastatic colorectal cancer: analyses 
of the ARIES observational cohort study. Pharmacoepidemiol 
Drug Saf [Internet]. 2014;23(7):726–34. Available from: http://
dx.doi.org/10.1002/pds.3633.
 85. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, 
Hedrick E, et al. Bevacizumab beyond first progression is asso-
ciated with prolonged overall survival in metastatic colorectal 
cancer: results from a large observational cohort study (BRiTE). 
J Clin Oncol [Internet]. 2008;26(33):5326–34. Available from: 
http://dx.doi.org/10.1200/jco.2008.16.3212.
 86. Basso M, Dadduzio V, Ardito F, Lombardi P, Strippoli A, Vel-
lone M, et al. Conversion chemotherapy for technically unre-
sectable colorectal liver metastases: a retrospective, STROBE-
compliant, single-center study comparing chemotherapy alone 
and combination chemotherapy with cetuximab or bevacizumab. 
Medicine [Internet]. 2016;95(20):e3722. Available from: http://
dx.doi.org/10.1097/MD.00000 00000 00372 2.
 87. Bai L, Wang F, Li Z-Z, Ren C, Zhang D-S, Zhao Q, et al. Chemo-
therapy plus bevacizumab versus chemotherapy plus cetuximab 
as first-line treatment for patients with metastatic colorectal 
cancer: results of a registry-based cohort analysis. Medicine 
[Internet]. 2016;95(51):e4531. Available from: http://dx.doi.
org/10.1097/MD.00000 00000 00453 1.
 88. Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effec-
tiveness of bevacizumab with first-line combination chemo-
therapy for medicare patients with stage IV colorectal cancer. J 
Clin Oncol [Internet]. 2012;30(6):608–15. Available from: http://
dx.doi.org/10.1200/jco.2011.38.9650.
 89. Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi 
E, et al. Maintenance single-agent bevacizumab or observation 
after first-line chemotherapy in patients with metastatic colorec-
tal cancer: a multicenter retrospective study. Invest New Drugs 
[Internet]. 2013;31(4):1035–43. Available from: http://dx.doi.
org/10.1007/s1063 7-013-9936-9.
 90. Lu Z-H, Peng J-H, Wang F-L, Yuan Y-F, Jiang W, Li Y-H, 
et  al. Bevacizumab with preoperative chemotherapy versus 
preoperative chemotherapy alone for colorectal cancer liver 
metastases: a retrospective cohort study. Medicine [Internet]. 
2016;95(35):e4767. Available from: http://dx.doi.org/10.1097/
MD.00000 00000 00476 7.
 91. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hains-
worth J, Heim W, et al. Bevacizumab plus irinotecan, fluoroura-
cil, and leucovorin for metastatic colorectal cancer. N Engl J Med 
[Internet]. 2004;350(23):2335–42. Available from: http://dx.doi.
org/10.1056/NEJMo a0326 91.
 92. Chang SM. The Agency for Healthcare Research and Qual-
ity (AHRQ) effective health care (EHC) program methods 
guide for comparative effectiveness reviews: keeping up-to-
date in a rapidly evolving field. J Clin Epidemiol [Internet]. 
2011;64(11):1166–7. Available from: http://dx.doi.org/10.1016/j.
jclin epi.2011.08.004.
 93. Silva HP, Petramale CA, Elias FTS. Avanços e desafios da 
política nacional de gestão de tecnologias em saúde. Revista de 
Saúde Pública [Internet]. 2012;46(suppl 1):83–90. Available 
from: http://dx.doi.org/10.1590/s0034 -89102 01200 50000 60.
 94. Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios 
S, Stathopoulos J, et al. Treatment of colorectal cancer with 
and without bevacizumab: a phase III study. Oncology [Inter-
net]. 2010;78(5–6):376–81. Available from: http://dx.doi.
org/10.1159/00032 0520.
 95. Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana 
A, et al. Effectiveness of bevacizumab added to standard chemo-
therapy in metastatic colorectal cancer: final results for first-line 
treatment from the ITACa randomized clinical trial. Ann Oncol 
[Internet]. 2015 ;26(6):1201–7. Available from: http://dx.doi.
org/10.1093/annon c/mdv13 0.
 96. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth 
JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoro-
pyrimidine regimens with or without bevacizumab as first-line 
treatment of metastatic colorectal cancer: results of the TREE 
Study. J Clin Oncol [Internet]. 2008;26(21):3523–9. Available 
from: http://dx.doi.org/10.1200/JCO.2007.15.4138.
 97. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitch-
ell EP, Alberts SR, et al. Bevacizumab in combination with 
606 W. C. da Silva et al.
oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previ-
ously treated metastatic colorectal cancer: results from the East-
ern Cooperative Oncology Group Study E3200. J Clin Oncol 
[Internet]. 2007;25(12):1539–44. Available from: http://dx.doi.
org/10.1200/jco.2006.09.6305.
 98. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, 
Wong R, et al. Bevacizumab in combination with oxaliplatin-
based chemotherapy as first-line therapy in metastatic colorectal 
cancer: a randomized phase III study. J Clin Oncol [Internet]. 
2008;26(12):2013–9. Available from: http://dx.doi.org/10.1200/
JCO.2007.14.9930.
 99. Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro 
S, et al. Bevacizumab in association with de Gramont 5-fluo-
rouracil/folinic acid in patients with oxaliplatin-, irinotecan-, 
and cetuximab-refractory colorectal cancer. Cancer [Inter-
net]. 2009;115(20):4849–56. Available from: http://dx.doi.
org/10.1002/cncr.24540 .
 100. Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan Z-Z, 
Mitchell L, et al. Efficacy and safety of bevacizumab in metastatic 
colorectal cancer: pooled analysis from seven randomized con-
trolled trials. Oncologist [Internet]. 2013;18(9):1004–12. Avail-
able from: http://dx.doi.org/10.1634/theon colog ist.2013-0107.
 101. Heinemann V, von Weikersthal LF, Decker T, Kiani A, 
Vehling-Kaiser U, Al-Batran S-E, et al. FOLFIRI plus cetuxi-
mab versus FOLFIRI plus bevacizumab as first-line treatment 
for patients with metastatic colorectal cancer (FIRE-3): a ran-
domised, open-label, phase 3 trial. Lancet Oncol [Internet]. 
2014;15(10):1065–75. Available from: http://dx.doi.org/10.1016/
S1470 -2045(14)70330 -4.
 102. Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack 
JW, Keating NL, et  al. Patients’ expectations about effects 
of chemotherapy for advanced cancer. N Engl J Med [Inter-
net]. 2012;367(17):1616–25. Available from: http://dx.doi.
org/10.1056/NEJMo a1204 410.
 103. New 50 million pound cancer fund already intellectually bank-
rupt. Lancet. 2010;376(9739):389.
 104. Thompson DF. Understanding financial conflicts of interest. N 
Engl J Med. 1993;329:573–6.
 105. Silva TBC, Almeida PHRF, Araújo VE, Acurcio FA, Guerra 
Júnior AA, Godman B, et al. Effectiveness and safety of insulin 
glargine versus detemir analysis in patients with type 1 diabe-
tes: systematic review and meta-analysis. Ther Adv Endocrinol 
Metab. 2018;9(8):241–54.
 106. Davis C, Abraham J. Is there a cure for corporate crime in the 
drug industry? BMJ. 2013;346:f755.
 107. Civaner M. Sale strategies of pharmaceutical companies in a 
‘‘pharmerging’’ country: the problems will not improve if the 
gaps remain. Health Policy. 2012;106:225–32.
 108. Cohen D. Dabigatran: how the drug company withheld important 
analyses. BMJ. 2014;349:g467.
 109. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry 
sponsorship and research outcome: systematic review with meta-
analysis. Intensive Care Med. 2018;44:1603–12.
 110. Hakoum MB, Anouti S, Al-Gibbawi M, Abou-Jaoude EA, Has-
bani DJ, Lopes LC, Agarwal A, Guyatt G, Akl EA. Reporting 
of financial and non-financial conflicts of interest by authors 
of systematic reviews: a methodological survey. BMJ Open. 
2016;6:e011997.
Affiliations
Wânia Cristina da Silva1  · Vânia Eloisa de Araujo1,2  · Ellias Magalhães e Abreu Lima3 · 
Jessica Barreto Ribeiro dos Santos1  · Michael Ruberson Ribeiro da Silva1  · 
Paulo Henrique Ribeiro Fernandes Almeida1  · Francisco de Assis Acurcio1,4  · Brian Godman5,6,7,8  · 
Amanj Kurdi5,9  · Mariângela Leal Cherchiglia1,4  · Eli Iola Gurgel Andrade1,4 
 Wânia Cristina da Silva 
 wania_logistica@hotmail.com
 Vânia Eloisa de Araujo 
 vaniaearaujo@gmail.com
 Ellias Magalhães e Abreu Lima 
 ellias_lima@hotmail.com
 Jessica Barreto Ribeiro dos Santos 
 jessicabarreto2203@gmail.com
 Michael Ruberson Ribeiro da Silva 
 mruberson@gmail.com
 Paulo Henrique Ribeiro Fernandes Almeida 
 henriqueribeiro.farm@gmail.com
 Francisco de Assis Acurcio 
 fracurcio@gmail.com
 Amanj Kurdi 
 amanj.baker@strath.ac.uk
 Mariângela Leal Cherchiglia 
 mcherchiglia@gmail.com
 Eli Iola Gurgel Andrade 
 eliola51@gmail.com; iola@medicina.ufmg.br
1 Postgraduate Program in Medicines and Pharmaceutical 
Services, School of Pharmacy, Federal University of Minas 
Gerais, Belo Horizonte, Brazil
2 School of Dentistry, Pontifical Catholic University of Minas 
Gerais, Belo Horizonte, Brazil
3 Mario Penna Institut of Oncology–Minas Gerais, 
Belo Horizonte, Brazil
4 Postgraduate Program in Public Health, School 
of Medicine, Federal University of Minas Gerais (UFMG), 
Belo Horizonte, Brazil
5 Strathclyde Institute of Pharmacy and Biomedical Sciences, 
University of Strathclyde, Glasgow, UK
6 Division of Clinical Pharmacology, Department 
of Laboratory Medicine, Karolinska Institutet, Karolinska 
University Hospital Huddinge, Stockholm, Sweden
7 Health Economics Centre, University of Liverpool 
Management School, Liverpool, UK
8 School of Pharmacy, Sefako Makgatho Health Sciences 
University, Garankuwa, Pretoria, South Africa
9 Department of Pharmacology, College of Pharmacy, Hawler 
Medical University, Erbil, Iraq
